HomeCompareCIHKY vs JNJ

CIHKY vs JNJ: Dividend Comparison 2026

CIHKY yields 6.15% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CIHKY wins by $206.3K in total portfolio value
10 years
CIHKY
CIHKY
● Live price
6.15%
Share price
$31.93
Annual div
$1.96
5Y div CAGR
36.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$236.6K
Annual income
$97,622.70
Full CIHKY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CIHKY vs JNJ

📍 CIHKY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCIHKYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CIHKY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CIHKY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CIHKY
Annual income on $10K today (after 15% tax)
$523.02/yr
After 10yr DRIP, annual income (after tax)
$82,979.30/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CIHKY beats the other by $78,993.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CIHKY + JNJ for your $10,000?

CIHKY: 50%JNJ: 50%
100% JNJ50/50100% CIHKY
Portfolio after 10yr
$133.4K
Annual income
$51,156.05/yr
Blended yield
38.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CIHKY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
0.3
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CIHKY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCIHKYJNJ
Forward yield6.15%2.13%
Annual dividend / share$1.96$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR36.5%28%
Portfolio after 10y$236.6K$30.3K
Annual income after 10y$97,622.70$4,689.40
Total dividends collected$199.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CIHKY vs JNJ ($10,000, DRIP)

YearCIHKY PortfolioCIHKY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,540$839.91$10,592$272.30+$948.00CIHKY
2$13,584$1,236.47$11,289$357.73+$2.3KCIHKY
3$16,392$1,856.79$12,123$472.89+$4.3KCIHKY
4$20,398$2,858.29$13,141$629.86+$7.3KCIHKY
5$26,363$4,537.39$14,408$846.81+$12.0KCIHKY
6$35,689$7,481.15$16,021$1,151.60+$19.7KCIHKY
7$51,108$12,920.04$18,122$1,588.22+$33.0KCIHKY
8$78,288$23,602.62$20,930$2,228.20+$57.4KCIHKY
9$129,891$46,122.97$24,792$3,191.91+$105.1KCIHKY
10$236,606$97,622.70$30,274$4,689.40+$206.3KCIHKY

CIHKY vs JNJ: Complete Analysis 2026

CIHKYStock

China Merchants Bank Co., Ltd., together with its subsidiaries, provides various banking products and services. It operates through Wholesale Finance Business, Retail Finance Business, and Other Business segments. The company offers current, demand, time, call, savings, notice, and renminbi accounts. Its loan products include personal commercial real estate, consumption, housing, and car loans; loans to finance for studying abroad; micro-business loans; mortgage loans for equipment; joint guarantee, special guarantee, and housing mortgage loan; bank acceptance, discount, liquid capital, and fixed asset loans; and loans for vessels. The company also offers credit cards; insurance products; open-ended funds; discount and guarantees for commercial bills, redemption of commercial bills, and guaranteed discount for commercial acceptance bills; and financial consultation, debt financing underwriting, merger and acquisition financing, and equity financing and enterprise listing services. In addition, it provides forfeiting and risk participation, escrow, cross-border RMB clearing, and interbank services; and risk and financial management, cross-border RMB and oversea financing, international factoring and settlement, and trade finance services. Further, the company offers financial leasing and guarantee, investment and wealth management, forex option and gold trading, forex express trading, international, offshore and private banking, custody, pension, and electronic banking services. As of December 31, 2021, it operated 143 branches; 1,770 sub-branches; one branch-level operation center; 2,812 self-service centers; 6,592 self-service machines; one representative office; 14,746 visual counters in Mainland China. The company also operates in Hong Kong, New York, London, Singapore, Luxembourg, Sydney, and Taipei. China Merchants Bank Co., Ltd. was founded in 1987 and is headquartered in Shenzhen, China.

Full CIHKY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CIHKY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CIHKY vs SCHDCIHKY vs JEPICIHKY vs OCIHKY vs KOCIHKY vs MAINCIHKY vs ABBVCIHKY vs MRKCIHKY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.